These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 34905446)

  • 21. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up.
    Carryn S; Feyssaguet M; Povey M; Di Paolo E
    Vaccine; 2019 Aug; 37(36):5323-5331. PubMed ID: 31345639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antibody persistence following on different vaccination strategies of domestic measles, mumps and rubella combined attenuated live vaccine: a 3-year follow-up study].
    He HQ; Li Q; Yan R; Zhou Y; Tang XW; Deng X; Xie SY; Chen ZP
    Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Apr; 51(4):336-340. PubMed ID: 28395468
    [No Abstract]   [Full Text] [Related]  

  • 23. Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in healthy Brazilian infants: a randomized non-inferiority study.
    de Menezes Martins R; Curran B; Maia Mde L; Ribeiro Md; Camacho LA; da Silva Freire M; Yamamura AM; Siqueira MM; Lemos MC; de Albuquerque EM; von Doellinger Vdos R; Homma A; Saganic L; Jarrahian C; Royals M; Zehrung D
    Contemp Clin Trials; 2015 Mar; 41():1-8. PubMed ID: 25476584
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of live attenuated Japanese encephalitis SA 14-14-2 vaccine among Sri Lankan children with previous receipt of inactivated JE vaccine.
    Wijesinghe PR; Abeysinghe MRN; Yoksan S; Yao Y; Zhou B; Zhang L; Fleming JA; Marfin AA; Victor JC
    Vaccine; 2016 Nov; 34(48):5923-5928. PubMed ID: 27773472
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and Safety of an Inactivated Enterovirus 71 Vaccine Administered Simultaneously With Hepatitis B Vaccine and Group A Meningococcal Polysaccharide Vaccine: A Phase 4, Open-Label, Single-Center, Randomized, Noninferiority Trial.
    Zhang Z; Liang Z; Zeng J; Zhang J; He P; Su J; Zeng Y; Fan R; Zhao D; Ma W; Zeng G; Zhang Q; Zheng H
    J Infect Dis; 2019 Jul; 220(3):392-399. PubMed ID: 30891604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune non-interference and safety study of Vi-DT typhoid conjugate vaccine with a measles, mumps and rubella containing vaccine in 9-15 months old Nepalese infants.
    Saluja T; Rai GK; Chaudhary S; Kanodia P; Giri BR; Kim DR; Yang JS; Park IY; Kyung SE; Vemula S; Reddy E J; Kim B; Gupta BP; Jo SK; Ryu JH; Park HK; Shin JH; Lee Y; Kim H; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
    Vaccine; 2022 Sep; 40(40):5828-5834. PubMed ID: 36064672
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study.
    Klein NP; Abu-Elyazeed R; Povey M; Macias Parra M; Diez-Domingo J; Ahonen A; Korhonen T; Tinoco JC; Weiner L; Marshall GS; Silas PE; Sarpong KO; Ramsey KP; Fling JA; Speicher D; Campos M; Munjal I; Peltier C; Vesikari T; Baccarini C; Caplanusi A; Gillard P; Carryn S; Henry O
    J Pediatric Infect Dis Soc; 2020 Apr; 9(2):194-201. PubMed ID: 30849175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: Results of a randomized, comparative, active controlled phase III clinical trial.
    Sood A; Mitra M; Joshi HA; Nayak US; Siddaiah P; Babu TR; Mahapatro S; Sanmukhani J; Gupta G; Mittal R; Glueck R
    Hum Vaccin Immunother; 2017 Jul; 13(7):1523-1530. PubMed ID: 28362563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines.
    Schwarzer S; Reibel S; Lang AB; Struck MM; Finkel B; Gerike E; Tischer A; Gassner M; Glück R; Stück B; Cryz SJ
    Vaccine; 1998; 16(2-3):298-304. PubMed ID: 9607046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.
    Feiterna-Sperling C; Brönnimann R; Tischer A; Stettler P; Durrer P; Gaedicke G
    Pediatr Infect Dis J; 2005 Dec; 24(12):1083-8. PubMed ID: 16371870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Measles, mumps, rubella vaccine (Priorix; GSK-MMR): a review of its use in the prevention of measles, mumps and rubella.
    Wellington K; Goa KL
    Drugs; 2003; 63(19):2107-26. PubMed ID: 12962524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella.
    Nascimento Silva JR; Camacho LA; Siqueira MM; Freire Mde S; Castro YP; Maia Mde L; Yamamura AM; Martins RM; Leal Mde L;
    Vaccine; 2011 Aug; 29(37):6327-34. PubMed ID: 21640779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and safety of measles-mumps-rubella vaccine delivered by disposable-syringe jet injector in India: A randomized, parallel group, non-inferiority trial.
    Bavdekar A; Oswal J; Ramanan PV; Aundhkar C; Venugopal P; Kapse D; Miller T; McGray S; Zehrung D; Kulkarni PS;
    Vaccine; 2018 Feb; 36(9):1220-1226. PubMed ID: 29395526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new combination vaccine for measles, mumps, rubella and varicella.
    Zareba G
    Drugs Today (Barc); 2006 May; 42(5):321-9. PubMed ID: 16801995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Similar immunogenicity of measles-mumps-rubella (MMR) vaccine administrated at 8 months versus 12 months age in children.
    He H; Chen E; Chen H; Wang Z; Li Q; Yan R; Guo J; Zhou Y; Pan J; Xie S
    Vaccine; 2014 Jun; 32(31):4001-5. PubMed ID: 24837773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Immunogenicity and safety of a boost dose of measles, mumps, and rubella combined vaccine for 4-6 years old children].
    Xiao YH; Chang SY; Bai S; Zhao RM; Wang JH; Wang XQ; Yang YK; Ma YL; Liu XQ; Luo LY; Lyu M; Chen HP
    Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Jun; 42(6):1086-1091. PubMed ID: 34814512
    [No Abstract]   [Full Text] [Related]  

  • 38. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Marin M; Broder KR; Temte JL; Snider DE; Seward JF;
    MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety, reactogenicity and immunogenicity of the live attenuated combined measles, mumps and rubella vaccine containing the RIT 4385 mumps strain in healthy Singaporean children.
    Lim FS; Han HH; Bock HL
    Ann Acad Med Singap; 2007 Dec; 36(12):969-73. PubMed ID: 18185875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.
    Kim DS; Houillon G; Jang GC; Cha SH; Choi SH; Lee J; Kim HM; Kim JH; Kang JH; Kim JH; Kim KH; Kim HS; Bang J; Naimi Z; Bosch-Castells V; Boaz M; Bouckenooghe A
    Hum Vaccin Immunother; 2014; 10(9):2656-63. PubMed ID: 25483480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.